Patients who undergo cystectomy due to bladder cancer can elect an ileal conduit or a neobladder for urinary diversion. Decision regret related to this choice is an important and undesirable patient reported outcome. Our objective was to compare the severity of decision regret experienced by patients with a neobladder vs an ileal conduit.
We analyzed data from a longitudinal cohort study of patients who underwent cystectomy from 2013 to 2015. We applied multivariable linear regression to examine associations of the urinary diversion method (neobladder vs ileal conduit) with decision regret measured with the DRS (Decision Regret Scale) 6 and 18 months after cystectomy. Covariates included demographic and clinical characteristics, health care utilization and complications after cystectomy, quality of life and factors related to the decision making process, including informed and shared decision making, and goal concordance.
Of the 192 patients in our cohort 141 received an ileal conduit and 51 received a neobladder. We observed no significant difference in the DRS score in patients with a neobladder vs an ileal conduit at 6 or 18 months (b=-1.28, 95% CI -9.07-6.53, vs b=-1.55, 95% CI -12.48-9.38). However, informed decision making was negatively related to decision regret at 6 and 18 months (b=-13.08, 95% CI -17.05--9.11, and b=-8.54, 95% CI -4.26--2.63, respectively). Quality of life was negatively associated with decision regret at 18 months (b=-5.50, 95% CI -8.95--2.03).
Patients treated with cystectomy who were more informed about bladder reconstruction options experienced less regret independent of the method selected. Efforts to inform and prepare patients for the bladder reconstruction decision may help prevent decision regret.
The Journal of urology. 2019 Aug 23 [Epub]
Devon K Check, Michael C Leo, Matthew P Banegas, Joanna E Bulkley, Kim N Danforth, Scott M Gilbert, Marilyn L Kwan, Maureen O'Keeffe Rosetti, Carmit K McMullen
Department of Population Health Sciences, Duke University School of Medicine and Duke Cancer Institute, Durham, North Carolina., Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon., Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California., H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Division of Research, Kaiser Permanente Northern California, Oakland, California.